Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY11 | Q96G91 | 6/20 | 0.80 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.80 |
| ▸ | RECQL | P46063 | 5/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.80 |
| ▸ | TIMP3 | P35625 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | PKM | P14618 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.80 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.80 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.80 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.80 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.80 |
| ▸ | ENTPD3 | O75355 | 1/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11477425 | 0.93 | P2RY11 (0.79) | P2RY11HPSERECQLKMT2AHSD17B10 | |
| SCHEMBL11510571 | 0.92 | P2RY11 (0.83) | P2RY11HPSERECQLKMT2AHSD17B10 | |
| SCHEMBL375680 | 0.90 | TIMP3 (0.75) | P2RY11HPSERECQLKMT2AHSD17B10 | |
| SCHEMBL17903265 | 0.90 | P2RY11 (0.78) | P2RY11HPSERECQLKMT2AHSD17B10 | |
| SCHEMBL16255254 | 0.90 | P2RY11 (0.84) | P2RY11HPSERECQLKMT2AHSD17B10 | |
| SCHEMBL16404704 | 0.89 | P2RY11 (0.86) | P2RY11HPSERECQLKMT2AHSD17B10 | |
| SCHEMBL5501853 | 0.89 | P2RY11 (0.77) | P2RY11HPSERECQLKMT2AHSD17B10 | |
| Suramin SCHEMBL30552218 | 0.89 | P2RY11 (1.00) | P2RY11HPSERECQLKMT2AHSD17B10 | |
| Suramin SCHEMBL30312075 | 0.89 | P2RY11 (1.00) | P2RY11HPSERECQLKMT2AHSD17B10 | |
| Suramin SCHEMBL29357785 | 0.89 | P2RY11 (1.00) | P2RY11HPSERECQLKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624753-B1 | PURINERGIC MODULATION OF SMELL | UNIV UTAH RES FOUND (US) | 2012-01-25 | — | — | EP | claimed |
| US-9901624-B2 | Methods and compositions for treating nephrogenic diabetes insipidus | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170035859-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | KISHORE BELLAMKONDA K (US) | 2017-02-09 | — | — | US | disclosed |
| EP-1807065-B1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | UNIV UTAH RES FOUND (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2410332-A1 | Method for identifying purinergic modulators of the olfactory system | The University Of Utah (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20090297497-A1 | Methods and compositions for treating nephrogenic diabetes and insipidus | NATIONAL INSTITUTES OF HEALTH | 2009-12-03 | — | — | US | disclosed |
| US-7557092-B2 | Purinergic modulation of smell | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-07-07 | — | — | US | disclosed |
| US-20060264398-A1 | Purinergic modulation of smell | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-11-23 | — | — | US | disclosed |
| US-4229584-A | Ureylenebis(anionic substituted phenylene carbonyl)imino naphthalene sulfonic acids and naphthalene carboxylic acids and their salts | AMERICAN CYANAMID COMPANY (US) | 1980-10-21 | — | — | US | disclosed |
| US-4229371-A | INHIBITORS OF THE COMPLEMENT SYSTEM, IMMUNOLOGY | AMERICAN CYANAMID COMPANY (US) | 1980-10-21 | — | — | US | disclosed |
| US-4117003-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4107201-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
| US-4107202-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
| US-4102917-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
| US-4102918-A | Anionic phenylcarboxamide complement inhibitors | AMERICAN CYANAMID COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
| US-4096174-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4089974-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-4087613-A | 1,3,5- Or 1,3,6-naphthalenetriyltris(sulfonylimino)aryl acids and salts | AMERICAN CYANAMID COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4061627-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-4020160-A | METABOLIC PROCESSES, ANTIINFLAMMATORY, ANTICOAGULANTS, ANTI-FIBRINOLYSIS, AND ANTIBODY-ANTIGEN REACTIVE | AMERICAN CYANAMID COMPANY (US) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264398-A1 | Purinergic modulation of smell | P2RX5, P2RX3, P2RX6 | P2RY11 57/4885HPSE 2820/4885RECQL 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.